Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Clinical trial NCT03801525 · TERMINATED
Trial details
- NCT number
- NCT03801525
- Sponsor
- TG Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-16
- Primary completion
- 2022-12-20
- Enrollment
- 277
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.